Seelos Therapeutics, Inc. is a clinical-stage bio-pharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system (CNS) disorders and in rare diseases. The Company’s portfolio includes several late-stage clinical assets targeting psychiatric and movement disorders, including orphan diseases. Seelos is based in New York, New York. Seelos’ common stock is traded on The Nasdaq Capital Market under the symbol "SEEL".
View Top Employees from Seelos Therapeutics, Inc.Website | http://www.seelostherapeutics.com |
Ticker | SEEL |
Revenue | $2 million |
Employees | 26 (26 on RocketReach) |
Founded | 2016 |
Address | 300 Park Avenue 2nd Floor, New York, New York 10022, US |
Phone | (646) 293-2100 |
Fax | (609) 208-1868 |
Technologies |
JavaScript,
HTML,
PHP
+8 more
(view full list)
|
Industry | Biotechnology, Business Services General, Business Services |
Competitors | MacroChem Corporation, Nephrogenex, NeurOp, Inc., Yaupon Therapeutics, Inc |
SIC | SIC Code 283 Companies, SIC Code 873 Companies, SIC Code 28 Companies, SIC Code 87 Companies |
NAICS | NAICS Code 54 Companies, NAICS Code 541 Companies, NAICS Code 54192 Companies, NAICS Code 541921 Companies, NAICS Code 5419 Companies |
Looking for a particular Seelos Therapeutics, Inc. employee's phone or email?
The Seelos Therapeutics, Inc. annual revenue was $2 million in 2024.
Michael Golembiewski is the CFO of Seelos Therapeutics, Inc..
26 people are employed at Seelos Therapeutics, Inc..
Seelos Therapeutics, Inc. is based in New York, New York.
The NAICS codes for Seelos Therapeutics, Inc. are [54, 541, 54192, 541921, 5419].
The SIC codes for Seelos Therapeutics, Inc. are [283, 873, 28, 87].